Literature DB >> 22718204

Serum cortisol and testosterone levels in chronic central serous chorioretinopathy.

Hasan Ali Tufan1, Baran Gencer, Arzu Taskiran Comez.   

Abstract

PURPOSE: To investigate the potential role of serum cortisol and testosterone levels in chronic central serous chorioretinopathy (CSC).
MATERIAL AND METHODS: Serum cortisol and testosterone levels of six male patients with chronic CSC were evaluated by chemiluminescent immunassay. Hormone levels were compared with the normal reference values of healthy people.
RESULTS: All patients were male, and the median age was 48 years (range: 42-54). The median duration of visual disturbance at presentation was 23 months (range: 12-48). Median 8:00 a.m. serum cortisol level was 11.6 μg/dl (min. 4.74, max. 18.3) and the cortisol levels were within the normal range in five of the six patients. All patients had normal serum testosterone levels, with a median value of 549.5 ng/ml (min. 246, max. 794).
CONCLUSION: Serum cortisol and testosterone levels were within normal ranges and in patients with chronic CSC. The association between these hormones and chronic CSC might be weak.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22718204     DOI: 10.1007/s00417-012-2075-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  21 in total

1.  Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex.

Authors:  A M Thoelen; P P Bernasconi; C Schmid; E P Messmer
Journal:  Retina       Date:  2000       Impact factor: 4.256

Review 2.  Idiopathic central serous chorioretinopathy.

Authors:  D Hussain; J D Gass
Journal:  Indian J Ophthalmol       Date:  1998-09       Impact factor: 1.848

3.  Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues.

Authors:  E M Rocha; L A Wickham; L A da Silveira; K L Krenzer; F S Yu; I Toda; B D Sullivan; D A Sullivan
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

4.  Type A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Trans Am Ophthalmol Soc       Date:  1986

5.  Pathogenesis of disciform detachment of the neuroepithelium.

Authors:  J D Gass
Journal:  Am J Ophthalmol       Date:  1967-03       Impact factor: 5.258

6.  Maculopathy a corticosteroid side-effect.

Authors:  I S Jain; K Singh
Journal:  J All India Ophthalmol Soc       Date:  1966-12

7.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

8.  Central serous chorioretinopathy in endogenous hypercortisolism.

Authors:  E A Bouzas; M H Scott; G Mastorakos; G P Chrousos; M I Kaiser-Kupfer
Journal:  Arch Ophthalmol       Date:  1993-09

9.  Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy.

Authors:  Catherine B Meyerle; K Bailey Freund; Pawan Bhatnagar; Viral Shah; Lawrence A Yannuzzi
Journal:  Retina       Date:  2007-09       Impact factor: 4.256

10.  Serum cortisol and testosterone levels in idiopathic central serous chorioretinopathy.

Authors:  Shaik M Zakir; M Shukla; Zaka-Ur-Rab Simi; J Ahmad; Mahmood Sajid
Journal:  Indian J Ophthalmol       Date:  2009 Nov-Dec       Impact factor: 1.848

View more
  11 in total

1.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

2.  The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels.

Authors:  Emine Çiloğlu; Fikret Unal; Nese Cetin Dogan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-18       Impact factor: 3.117

3.  Serum dehydroepiandrosterone sulphate, total antioxidant capacity, and total oxidant status in central serous chorioretinopathy.

Authors:  Fatih Mehmet Türkcü; Harun Yüksel; Hatice Yüksel; Alparslan Sahin; Yasin Cinar; Abdullah Kürşat Cingü; Muhammed Sahin; Ihsan Caça
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-06-08       Impact factor: 3.117

4.  A novel mutation of sgk-1 gene in central serous chorioretinopathy.

Authors:  Mahmut Akyol; Muhammet Kazım Erol; Ozdemir Ozdemir; Deniz Turgut Coban; Ahmet Burak Bilgin; Esin Sogutlu Sari; Elif Betul Turkoglu
Journal:  Int J Ophthalmol       Date:  2015-02-18       Impact factor: 1.779

5.  Association between endogenous cortisol level and the risk of central serous chorioretinopathy: a Meta-analysis.

Authors:  Zhi-Qiao Liang; Lyu-Zhen Huang; Jin-Feng Qu; Ming-Wei Zhao
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

6.  Comparison of Serum Cortisol and Testosterone Levels in Acute and Chronic Central Serous Chorioretinopathy.

Authors:  Tanie Natung; Avonuo Keditsu
Journal:  Korean J Ophthalmol       Date:  2015-11-25

7.  Risk Factors for Persistent or Recurrent Central Serous Chorioretinopathy.

Authors:  Jia Yu; Gezhi Xu; Qing Chang; Xiaofeng Ye; Lei Li; Chunhui Jiang; Qi Zhao
Journal:  J Ophthalmol       Date:  2019-08-14       Impact factor: 1.909

8.  Central Serous Chorioretinopathy and Blood Serotonin Concentrations.

Authors:  Takeshi Kimura; Takashi Araki; Yuki Komuku; Hisashi Iwami; Fumi Gomi
Journal:  J Clin Med       Date:  2021-02-03       Impact factor: 4.241

Review 9.  Gonadal Hormones and Retinal Disorders: A Review.

Authors:  Raffaele Nuzzi; Simona Scalabrin; Alice Becco; Giancarlo Panzica
Journal:  Front Endocrinol (Lausanne)       Date:  2018-03-02       Impact factor: 5.555

10.  Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy.

Authors:  Meenakshi Kumar; Elon H C van Dijk; Rajiv Raman; Pooja Mehta; Camiel J F Boon; Abhilash Goud; Seelam Bharani; Jay Chhablani
Journal:  BMC Ophthalmol       Date:  2020-03-06       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.